|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||36.71 - 37.22|
|52 Week Range||30.90 - 37.22|
|PE Ratio (TTM)||22.98|
|Forward Dividend & Yield||1.28 (3.49%)|
|1y Target Est||N/A|
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
The Dow hammered out an early lead Friday, as investors looked to the possible release of a reconciled GOP tax reform package later in the morning.
Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.
U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease. Xeljanz was approved as a 5-mg dose taken twice daily and as an extended-release 11-mg dose taken once daily as a drug for patients with active psoriatic arthritis who have not responded to other treatments. Psoriatic arthritis, a form of arthritis that affects some people who have skin disease psoriasis, is characterized by symptoms such as joint pain, stiffness and swelling.
Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.
Pfizer’s Oncology segment accounts for less than 20% of the company’s value, according to our estimates. For many other major pharma companies, their oncology portfolios are larger contributors to their top lines, and Pfizer has been looking to capitalize on opportunities in the space.
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]
The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer's Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn's disease and skin disorder plaque psoriasis, the drugmaker said. With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc's Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea's Samsung Bioepis Co Ltd.
Cellectis popped early Wednesday after it and Dow's Pfizer presented strong data for first in-human trials of a cancer therapy.
Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Roche recently sued Pfizer to block the latter’s biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in the U.S. for Roche in 2016. The fight is unlikely to stop there for Roche, as it has a lot more at stake.
Spark Therapeutics shares have plunged today, falling $27, or 37%, to $44.03 after the gene-therapy company released disappointing results for its treatment for hemophilia A at the American Society of Hematology’s annual meeting in Atlanta. The data on four patients in a phase 1/2 clinical trial showed some variability in the expression of Factor VIII, the clotting protein either missing or existing at very low levels in hemophilia A patients. It appears that Spark (ONCE) has lost the lead in developing a hemophilia A treatment to BioMarin Pharmaceutical (BMRN), a much larger biotechnology company that reported consistent levels of Factor VIII expression at the ASH conference in a phase 1/2 trial for its gene-therapy treatment.
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.